[Effect of Stressen on homocysteine blood levels in patients with cardiovascular disease or at risk by familial anamnesis].
OBJECTIVE
Moderate hyperhomocysteinemia, important risk factor for cardiovascular disease, produces an endothelial damage due to oxidative stress; high plasma levels of homocysteine can be related either to genetic aberrations or to reduced blood concentrations of folate and vitamin B12. The aim of this study is to evaluate the effect of Stressen on blood levels of this amino acid in patients affected by cardiovascular disease or in healthy hyperhomocysteinemic subjects, considered at risk of coronary diseases, due to familiar anamnesis.


METHODS
Homocysteinemia was evaluated by means of an immunoenzymatic method in 26 subjects with basal values > 15 micromol/l and treated with Stressen, a 10 ml bottle twice daily.


RESULTS
After 30 days of drug consumption, mean value of total homocysteinemia was 11.6 +/- 1.86 micromol/l, corresponding to a statistically significant mean reduction of 42.8% of basal values.


CONCLUSIONS
Stressen significantly decreased total homocysteinemia in this studied population, showing to be suitable for prevention of cardiovascular and thromboembolic diseases.
Mecarocci
D
D
Ospedale di Civita Castellana, Viterbo, Italia.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology* / Q000235:genetics / Q000517:prevention & control*; D003038:Cobamides / Q000008:administration & dosage / Q000627:therapeutic use*; D004151:Dipeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008487:Medical History Taking; D008875:Middle Aged; D012307:Risk Factors; D016896:Treatment Outcome
D003038:Cobamides; D004151:Dipeptides; D004338:Drug Combinations; D006710:Homocysteine; C000913:cobamamide; D002955:Leucovorin; C024362:arginine glutamate